Cytel | Joshua Schultz

Update: 2020-07-13

Description

In our fourth episode of the Portfolio Perspective we interview Joshua Shultz, CEO of Cytel, a company dedicated to shaping the future of drug development.

Join us as we discuss Cytel's experience working with private equity, the future of drug development, and how Cytel is helping in the global race to find a vaccine.

Comments

In Channel

private equity meets a pandemic | Adam Weinstein

2020-11-0912:42

p to the 4th, a new PE formula | Russ Steenberg

2020-09-2533:20

PE is a form of business, not finance | Steve Klinsky

2020-09-2516:25

Signify Health | Nathan Goldstein

2020-07-2725:02

Cytel | Joshua Schultz

2020-07-1329:50

eMids Technologies | Saurabh Sinha

2020-07-0519:16

ABB Optical | Angel Alvarez

2020-06-2927:49

NEST New York | Maria Dempsey

2020-06-2222:54

understanding globalization | Dr. Gary Gereffi

2020-06-1823:55

going global | Dr. David Robinson

2020-06-1026:52

can PE keep outperforming? | Dr. Steven Kaplan

2020-06-0115:44

when 140 characters isn't enough | Dr. Gregory Brown

2020-05-2719:50

data, data, data | Dr. Joshua Lerner

2020-05-2321:08

Introducing "Counting on Capital"

2020-05-1802:18

00:00

#box-pro-ellipsis-176054246065481{-webkit-line-clamp:2;}Cytel | Joshua Schultz

Cytel | Joshua Schultz

Shruti Rao

Cytel | Joshua Schultz